Suppr超能文献

一种基于国际调查的亨廷顿舞蹈病舞蹈症药物治疗算法

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease.

作者信息

Burgunder Jean-Marc, Guttman Mark, Perlman Susan, Goodman Nathan, van Kammen Daniel P, Goodman Lavonne

机构信息

Department of Neurology, University of Bern, Switzerland; Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario Canada; David Geffen School of Medicine at UCLA; Institute for Systems Biology, Seattle, WA; Formerly CHDI Foundation, Inc. Presently independent CNS development consultant and Huntington's Disease Drug Works, Lake Forest Park, WA.

出版信息

PLoS Curr. 2011 Aug 30;3:RRN1260. doi: 10.1371/currents.RRN1260.

Abstract

It is generally believed that treatments are available to manage chorea in Huntington's disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and side effect profiles, management of inadequate response to a single drug, and preferred drug when behavioral symptoms comorbid to chorea are present. Because there is lack of an evidence base to inform clinical decision-making, we surveyed an international group of experts to address these points. Survey results showed that patient stigma, physical injury, gait instability, work interference, and disturbed sleep were indications for a drug treatment trial. However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia. All experts chose an APD when comorbid psychotic or aggressive behaviors were present, or when active depression prevented the use of TBZ. However, there was agreement from all geographic regions that both APDs and TBZ were acceptable as monotherapy in other situations. Perceived efficacy and side effect profiles were similar for APDs and TBZ, except for depression as a significant side effect of TBZ. Experts used a combination of an APD and TBZ when treatment required both drugs for control of chorea and a concurrent comorbid symptom, or when severe chorea was inadequately controlled by either drug alone. The benzodiazepines (BZDs) were judged ineffective as monotherapy but useful as adjunctive therapy, particularly when chorea was exacerbated by anxiety. There was broad disagreement about the use of amantadine for chorea. Experts who had used amantadine described its benefit as small and transient. In addition to survey results, this report reviews available chorea studies, and lastly presents an algorithm for the treatment of chorea in HD which is based on expert preferences obtained through this international survey.

摘要

人们普遍认为,亨廷顿舞蹈症(HD)的舞蹈症状有相应的治疗方法。然而,由于缺乏证据,无法制定治疗指南。HD舞蹈症的研究文献未能涉及药物治疗的适应症、药物选择、药物剂量和副作用、单一药物疗效不佳时的处理方法,以及舞蹈症合并行为症状时的首选药物。由于缺乏指导临床决策的证据基础,我们对一组国际专家进行了调查,以解决这些问题。调查结果显示,患者的耻辱感、身体损伤、步态不稳、工作受影响以及睡眠障碍是进行药物治疗试验的指征。然而,专家们对于舞蹈症药物的首选并未达成一致,欧洲的大多数专家倾向于使用抗精神病药物(APD),而北美和澳大利亚的专家在APD和丁苯那嗪(TBZ)之间的首选比例几乎相同。当出现合并的精神病性或攻击性行为,或存在严重抑郁而无法使用TBZ时,所有专家都选择使用APD。然而,所有地理区域的专家都一致认为,在其他情况下,APD和TBZ作为单一疗法都是可以接受的。APD和TBZ的疗效和副作用相似,只是抑郁是TBZ的显著副作用。当治疗需要两种药物来控制舞蹈症和并发的合并症状,或严重舞蹈症单独使用任何一种药物都无法充分控制时,专家们会联合使用APD和TBZ。苯二氮卓类药物(BZD)作为单一疗法被认为无效,但作为辅助疗法有用,特别是当舞蹈症因焦虑而加重时。对于金刚烷胺用于舞蹈症的使用存在广泛分歧。使用过金刚烷胺的专家表示,其益处微小且短暂。除了调查结果外,本报告还回顾了现有的舞蹈症研究,最后提出了一种基于通过此次国际调查获得的专家偏好的HD舞蹈症治疗算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44f/3192325/7f32aa4bed24/figure-1.-drug-choices-all-regions.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验